Dolby Laboratories (DLB) Launches Dolby Vision 2 With Hisense, Is It Still Below Fair Value?
Dolby Laboratories (DLB) stock is back in focus after the company and Hisense launched Dolby Vision 2 on select televisions, with major streamers CANAL+, iQIYI, and Peacock committing to use the new capabilities.
See our latest analysis for Dolby Laboratories.
Alongside the Dolby Vision 2 rollout with Hisense and fresh commitments from streamers, Dolby Laboratories’ share price has gained clear short term momentum, with a 30 day share price return of 24.04% contrasting with a 1 year total shareholder return that is down 13%.
If this Dolby Laboratories move has your attention, it could be a good moment to widen your watchlist with 19 top founder-led companies
Dolby Laboratories stock now trades at a sizeable discount to both analyst targets and some intrinsic value estimates, even after the recent bounce. Is the market sensibly cautious given recent earnings, or overly skeptical about Dolby’s long term potential?
Most Popular Narrative: 21.1% Undervalued
Dolby Laboratories last closed at $61.77, while the most followed narrative puts fair value at $78.33, which suggests a sizeable valuation gap that hinges on a few key growth drivers.
Increasing content creation and distribution using Dolby Atmos and Dolby Vision across music, sports, film, and streaming demonstrates entrenched preference for high-quality, immersive experiences and cements Dolby as a technology standard, contributing to stable cash flows and resilient gross margins.
Curious what kind of revenue path and margin profile could support that higher fair value for Dolby Laboratories. The narrative leans on premium content adoption and future earnings power in a way that current pricing does not fully reflect.
Result: Fair Value of $78.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Dolby Laboratories still faces pressure if device makers push cheaper, royalty free codecs, or if weakness in TVs and set top boxes further limits licensing demand.
Find out about the key risks to this Dolby Laboratories narrative.
Next Steps
With both risks and rewards in play for Dolby Laboratories, it makes sense to move quickly and test the numbers yourself. Start by weighing the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond Dolby Laboratories?
If Dolby Laboratories is already on your radar, do not stop there. Use the same momentum to scan wider opportunities that could fit your goals and risk comfort.
- Spot potential mispricings early and review companies that currently appear overlooked through the screener containing 21 high quality undiscovered gems.
- Focus on financial resilience first and check candidates in the solid balance sheet and fundamentals stocks screener (48 results).
- Prioritise stability and capital preservation by assessing companies highlighted in the 83 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com